---
title: "OKYO Pharma Announces Purchase of Shares by Chief Executive Officer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293606238.md"
description: "On July 23, 2026, in London and New York, OKYO Pharma Limited (Nasdaq: OKYO) disclosed that their CEO, Robert J. Dempsey, acquired 15,000 of the company's ordinary shares on NASDAQ at a rate of $1.54 per share. OKYO Pharma is a clinical-stage biopharmaceutical firm focused on developing potential solutions for neuropathic corneal pain (NCP) and anterior segment eye conditions."
datetime: "2026-07-23T11:02:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293606238.md)
  - [en](https://longbridge.com/en/news/293606238.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293606238.md)
generator: "portal-rs"
---

# OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

On July 23, 2026, in London and New York, OKYO Pharma Limited (Nasdaq: OKYO) disclosed that their CEO, Robert J. Dempsey, acquired 15,000 of the company's ordinary shares on NASDAQ at a rate of $1.54 per share. OKYO Pharma is a clinical-stage biopharmaceutical firm focused on developing potential solutions for neuropathic corneal pain (NCP) and anterior segment eye conditions.

### Related Stocks

- [OKYO.US](https://longbridge.com/en/quote/OKYO.US.md)

## Related News & Research

- [OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial](https://longbridge.com/en/news/293646761.md)
- [OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial](https://longbridge.com/en/news/293487942.md)
- [Dogwood Therapeutics highlights Halneuron Phase 2b data readout timeline for chemotherapy-induced neuropathic pain program](https://longbridge.com/en/news/298049944.md)
- [CalciMedica implements 1-for-5 reverse stock split to address Nasdaq $1 minimum bid rule](https://longbridge.com/en/news/297786457.md)
- [DWTX: Halneuron shows promise as a scalable, effective CINP therapy with strong Phase 2 results](https://longbridge.com/en/news/297686345.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**